For Doctors in a Hurry
- Researchers investigated real world treatment patterns and clinical characteristics of patients with vitiligo across different age groups and disease severities.
- This retrospective cohort study analyzed data from 24,949 patients with vitiligo identified through linked healthcare claims and electronic health records.
- Approximately 27% to 32% of patients received no treatment, while median therapy durations ranged from 1.8 to 4.1 months.
- The researchers concluded that many patients remain untreated and those receiving therapy often experience short treatment durations with high variability.
- These findings highlight significant gaps in vitiligo management, suggesting a need for more consistent and sustained therapeutic interventions in clinical practice.
The Clinical Challenge of Pigment Restoration
Vitiligo is a chronic autoimmune condition that causes progressive skin depigmentation, often resulting in profound psychosocial distress and a diminished quality of life for affected patients [1, 2]. While the pathogenesis involves complex immune-mediated destruction of melanocytes, recent therapeutic advances have focused on modulating the Janus kinase pathway (a family of intracellular enzymes that mediate cytokine signaling) to arrest disease progression [3, 4]. Despite these developments, achieving repigmentation remains clinically difficult. Phase 3 trials of topical ruxolitinib 1.5% cream demonstrated that only 29.8% to 30.9% of patients achieved 75% facial repigmentation after 24 weeks of twice-daily application [3, 5]. Clinicians frequently rely on the Vitiligo Area Scoring Index (a standardized scale used to quantify the extent and degree of depigmentation) to monitor response, yet real-world management often deviates from controlled trial protocols [6, 7]. A retrospective cohort study of 24,949 patients now provides data on actual clinical practice in the United States, revealing that 27% to 32% of patients receive no treatment following their initial diagnosis [8].
Real-World Demographics and Disease Presentation
To capture a realistic picture of vitiligo management, researchers analyzed a large-scale retrospective cohort comprising 24,949 patients with at least three months of follow-up care. The demographic profile skewed heavily toward adults, with 21,996 patients (88.2%) aged 18 years or older at the time of their initial diagnosis. Female patients comprised 14,057 (56.3%) of the total population. When examining the anatomical distribution of the disease at the initial clinical encounter, the face was the most frequently affected area, impacting 5,482 of 16,674 patients (32.9%) who had a specific location recorded. For the practicing physician, this high rate of facial involvement underscores the need for early and proactive intervention, as depigmentation in highly visible areas strongly correlates with the severe psychological burden and social anxiety frequently reported by patients with this condition.
The Gap in Clinical Documentation and Severity Assessment
The study utilized deidentified data from the linked Komodo Healthcare Map and OMNY Health Foundation databases, capturing healthcare claims, pharmacy records, and electronic health records across US dermatology practices and other clinical settings. Participants were required to have at least 365 days of continuous healthcare plan enrollment prior to their first observed vitiligo diagnosis between January 2018 and August 2023. A striking finding regarding clinical documentation was the infrequent use of standardized severity metrics in everyday practice. The analysis revealed that only 1,329 patients (5.3%) had a body surface area (BSA) assessment recorded at the index date. This metric (a standardized calculation that quantifies the extent of depigmentation relative to the total skin surface) is essential for determining treatment intensity and monitoring disease progression. Among the small subset of patients who received this assessment, the majority presented with limited disease. Specifically, 963 patients had 10% or less BSA involvement, while 366 patients had greater than 10% BSA involvement. The lack of routine BSA documentation for the remaining 23,620 patients highlights a significant gap in standardized clinical monitoring, which likely hinders the ability of physicians to track therapeutic efficacy and adjust long-term management strategies.
Patterns of Pharmacologic Intervention and Age-Based Variations
Following the initial diagnosis, the most common pharmacologic interventions were topical and oral corticosteroids, alongside topical calcineurin inhibitors and phosphodiesterase-4 inhibitors. Treatment selection demonstrated distinct variations based on patient age, reflecting different clinical risk-benefit calculations for pediatric versus adult populations. Topical treatments were prescribed more frequently to children and adolescents, likely to mitigate the risks associated with systemic immunosuppression in developing bodies. In contrast, clinicians utilized systemic treatments more frequently for adults. Surprisingly, the study revealed a lack of correlation between the extent of skin involvement and the intensity of the prescribed regimen. There were no substantial differences in the types of treatments prescribed across different body surface area involvement groups during the follow-up period. Whether a patient presented with limited disease (10% or less body surface area) or more extensive depigmentation (greater than 10%), the therapeutic classes utilized remained consistent. Furthermore, the researchers observed high variability across treatment sequences, suggesting that there is no standardized therapeutic ladder currently guiding the management of vitiligo in US clinical practice.
Treatment Discontinuity and Sequence Variability
Despite the progressive nature of vitiligo and its known impact on patient well-being, a substantial portion of the cohort remained entirely untreated following their initial diagnosis. The researchers found that between 27% (6,308 of 23,620 patients without a body surface area assessment) and 32% (310 of 963 patients with 10% or less body surface area involvement) received no treatment for vitiligo during the follow-up period. This high rate of non-treatment suggests that many patients may be falling through the cracks, potentially due to barriers in access, patient preference, or a clinical assumption of disease stability. For those who did initiate therapy, the duration of treatment was notably brief. This is particularly concerning for a condition that typically requires months of consistent application to achieve visible repigmentation. The study reported that the median therapy duration for first and second lines of treatment ranged from 1.8 months (95% CI, 1.6 to 2.1) to 4.1 months (95% CI, 3.7 to 4.4), depending on the specific treatment type. These short intervals of pharmacologic use strongly indicate high rates of treatment discontinuation or premature switching between therapies before clinical efficacy can be fully evaluated. For the practicing physician, these findings underscore a critical need for improved patient education and longitudinal management strategies. Setting realistic expectations about the slow timeline of repigmentation may help ensure that patients remain on effective therapies long enough to achieve meaningful clinical outcomes.
References
1. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.. Lancet (London, England). 2020. doi:10.1016/S0140-6736(20)30609-7
2. Eleftheriadou V, Desai S, Bae JM, et al. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.. JAMA dermatology. 2026. doi:10.1001/jamadermatol.2026.0294
3. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2118828
4. Abadie MA, Tukmatchy H, Abadie M, Ball P, Morrissey H. An Update on Vitiligo Target Therapy: A Semi-Structured Systematic Review. 2023. doi:10.33140/mcr.08.11.04
5. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.. The New England journal of medicine. 2022. doi:10.1056/NEJMoa2118828
6. Peralta-Pedrero ML, Morales-Sánchez MA, Cruz FJ, Torre-García MEDL, Cruz-Peralta ES, Olguín-García MG. Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo.. The Australasian journal of dermatology. 2019. doi:10.1111/ajd.13008
7. Geel NV, Saeys I, Causenbroeck JV, et al. Image analysis systems to calculate the surface area of vitiligo lesions: A systematic review of measurement properties.. Pigment cell & melanoma research. 2022. doi:10.1111/pcmr.13056
8. Adiri R, Gauthier G, Kurosky SK, et al. Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.. JAMA dermatology. 2026. doi:10.1001/jamadermatol.2026.0971
